Diagnosis of Bone and Liver Metastases in Breast Cancer Comparing Tumor Markers and Imaging Techniques

1989 ◽  
Vol 4 (2) ◽  
pp. 103-105 ◽  
Author(s):  
P. Zanco ◽  
G. Rota ◽  
V. Sportiello ◽  
N. Borsato ◽  
G. Ferlin
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Bone Metastases ◽  
Tumor Markers ◽  
Imaging Techniques ◽  
Hepatic Metastases ◽  
Serum Levels ◽  
Serum Markers ◽  
Surgical Removal ◽  
Rule Out

One hundred and forty-seven patients were examined by bone scintigraphy, ultrasonography and scintigraphic scan of the liver, at different times after surgical removal of a breast cancer, to rule out skeletal and hepatic metastases. At the same time as imaging procedures, serum levels of tumor markers (CEA, TPA and CA 15–3) were determined using radioimmunometric methods. One or more markers were elevated in all 13 patients with hepatic metastases; 9 out of 46 patients with bone metastases had all serum markers normal, with a sensitivity of 80%. Combined assay of the markers proved useful, TPA and CA 15–3 showing the best sensitivity in bone metastases, and all three markers in liver metastases.

scholarly journals Correlation Between Bone Scintigraphy and Tumor Markers in Patients with Breast Carcinoma

2006 ◽  
Vol 6 (1) ◽  
pp. 75-77 ◽  
Author(s):  
Amela Begić ◽  
Elma Kučukalić-Selimović ◽  
Nermina Obralić ◽  
Osman Durić ◽  
Nadir Lačević ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Tumor Markers ◽  
Serum Levels ◽  
Whole Body ◽  
Chi Square ◽  
Breast Cancer Metastases ◽  
Cancer Early Detection ◽  
Cancer Metastases

A characteristic feature of many cancer types is their ability to metastasise to the skeleton. Bone is the most common site of metastatic invasion, after hematogenous spreading of breast cancer. Early detection of bone metastases is mandatory in the evaluation and management of these patients. Bone scintigraphy is commonly performed in detection and evaluation bone metastases. Tumor markers are present in healthy individuals as well as in patients with malignant diseases but in different concentration. Aim of study was to correlate serum levels of tumor marker Ca (15-3), CEA and presence of bone metastases detected by bone scintigraphy. Study included 25 patients with breast cancer, previously surgically treated. All patients underwent whole body scintigraphy. Ca (15-3) and CEA was measured by radioimmunoassay. Presence, number of bone metastases were correlated with Ca (15-3) and CEA levels. Median age of patients included in study was 50 varying from 30 to 67. Bone scintigraphy revealed bone metastases in 16 (64%) patients. A weak correlation was found between number of metastases and level of Ca (15-3) (r=0.139, p=0.254). Significant differences in Ca (15-3) level was found in patient with metastases compared to patients without metastases (chi square 0, p=1.0). Good correlation was found between number of metastases and serum level of CEA. Correlation between level of two tumor markers Ca (15-3) and CEA was a weak (r = 0.096 , p=0.323). Bone scintigraphy is a sensitive diagnostic toll for detecting breast cancer metastases to bone. Serum levels of tumor markes in isolation can not give complete accuracy about bone metastases.

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Tumor Biology ◽  
2007 ◽  
Vol 28 (1) ◽  
pp. 36-44 ◽  
Author(s):  
Michael H.R. Eichbaum ◽  
Thomas M. de Rossi ◽  
Sepp Kaul ◽  
Thomas Bruckner ◽  
Andreas Schneeweiss ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Hepatocyte Growth Factor ◽  
Liver Metastases ◽  
Serum Levels ◽  
Scatter Factor ◽  
Hepatocyte Growth

CA 15.3 with Urinary Calcium Excretion is Useful in the Diagnosis and Monitoring of Bone Metastases from Breast Cancer

1993 ◽  
Vol 8 (4) ◽  
pp. 208-214
Author(s):  
G.C. Yadav ◽  
A. Rao ◽  
M.M. Motawy ◽  
N. Safadi ◽  
M. Jameel Ahmed
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Serum Levels ◽  
Urinary Calcium ◽  
Response To Therapy ◽  
Urinary Calcium Excretion ◽  
Calcium Excretion ◽  
Diagnostic Efficacy ◽  
Ca 15.3

Serum levels of breast carcinoma antigen (CA 15.3) and urinary calcium excretion (UCa) were determined in 73 patients with breast cancer: 36 without bone metastases (stage I-IV) and 37 with bone metastases. The patients in the latter group were further investigated at 2,4 and 6 months from the start of treatment. Both markers showed significant elevations in the group with bone metastases (CA 15.3: P = 1.0×10–6, UCa: P = 8.6×10–9). The bone metastasis index (BMI), which represents the combination of the markers, had better diagnostic efficacy (90%) than CA 15.3 alone (84%) or UCa alone (82%). During treatment of bone metastasis, the longitudinal levels of the markers showed a highly significant association with the therapeutic response assessed by the UICC criteria. For identifying progression of disease, the diagnostic efficacy of CA 15.3, UCa and a combination of both, the so-called Biochemical Index of Response (BIR), was 65%, 70% and 79%, respectively, at two months and 89%, 84% and 92% at four months. Application of the tandem, CA 15.3 with UCa, was very useful for the detection of bone metastases and the prediction of response to therapy.

Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1105-1105
Author(s):  
L. Mercatali ◽  
T. Ibrahim ◽  
E. Sacanna ◽  
R. Ricci ◽  
E. Scarpi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Serum Markers

Serum CEA and CA 15-3 levels according to breast cancer subtypes.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11511-e11511 ◽  
Author(s):  
Isa Dede ◽  
Gungor Utkan ◽  
Hakan Akbulut ◽  
Yuksel Urun ◽  
Dilsa Mizrak ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Serum Levels ◽  
Carbohydrate Antigen ◽  
Breast Cancer Subtypes ◽  
Her2 Status ◽  
Cancer Subtypes ◽  
Serum Cea

e11511 Background: Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 are frequently elevated in patients with metastatic breast cancer (MBC). In this study we aimed to correlate levels according to breast cancersubtypes with MBC. Methods: From January 2008 to December 2012, ninety-eight patients with MBC who were treated at Ankara University School Of Medicine, Department of Medical Onkology were included in this study.Serum levels of CEA and CA 15-3were measured and compared according to tumor estrogen receptor (ER), progesteron receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. Results: In this cohort, overall ER,PR and HER2 positivity rates were 65 %,68%,and 58%, retrospectively. Positivite ER status was associated with elevated levels of CA 15-3 and cea. Of these, CA 15-3 levels elevated in 40.5% of ER positivite and 24.1 % of ER negativite patients (p=0.027). Similarly, 46.8 % of ER positivite and 18.2% of ER negativite patients had elevated levels of CEA (P=0.022). no association between PR and HER2 status and tumor markers was observed. Conclusions: The breast cancer subtypes are correlated with serum levels of tumor markers in patients with MBC. Tumor markers elevation may be associated with biological background of breast cancer subtypes. Further validation is needed to determine the role of these markers in diffrent tumor types for monitoring patients with MBC.

Serum Markers and Prognosis in Locally Advanced Breast Cancer

2005 ◽  
Vol 91 (6) ◽  
pp. 522-530 ◽  
Author(s):  
Javier Martínez-Trufero ◽  
Abigail Ruíz de Lobera ◽  
Juan Lao ◽  
Teresa Puértolas ◽  
Angel Artal-Cortés ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Serum Levels ◽  
Serum Markers ◽  
Baseline Serum ◽  
Ca 15.3 ◽  
Response To Neoadjuvant Chemotherapy

Background Locally advanced breast cancer (LABC) represents a heterogeneous subgroup of breast cancer with an often dismal outcome. Identifying prognostic factors has acquired great significance for the selection of optimal treatment in individual patients. Methods Between January 1993 and December 1997, 103 patients were treated in our institution with multimodality treatment consisting of neoadjuvant chemotherapy followed by surgery, adjuvant chemotherapy and radiotherapy; tamoxifen was added in hormone receptor-positive cases. In the search for prognostic factors well-established parameters (clinical, pathological and treatment-related) as well as new features with potential value (c-erbB-2, baseline serum levels of CA 15.3 and CEA) were included in the univariate and multivariate analysis. Results At a median follow-up of 92 months (range, 8-130), the estimated five-year cancer-specific overall survival (OS) and disease-free survival (DFS) were 71.34% and 57.7%, respectively. Among the 22 different variables studied, only 10 were significantly correlated with OS and DFS. In multivariate analysis five retained independent prognostic value for both OS and DFS: tumor grade, serum markers, features of inflammatory breast cancer (IBC), response to neoadjuvant chemotherapy and lymph node status. With cutoff values of 35 U/mL for CA 15.3 and 5 ng/mL for CEA, the probability of five-year OS (Cox hazard ratio 3.91, P = 0.0009) and DFS (Cox hazard ratio 2.40, P = 0.02) decreased from 78% to 52% and from 68% to 47%, respectively, when at least one of these markers was abnormal. Conclusions Baseline serum levels of CEA and CA 15.3 emerged from this study as strong independent predictors of outcome in LABC, whose value adds to other established prognostic factors such as postoperative nodal status, IBC, histological grade and response to neoadjuvant chemotherapy.

scholarly journals Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?

2006 ◽  
Vol 52 (3) ◽  
pp. 345-351 ◽  
Author(s):  
Michael J Duffy
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Primary Treatment ◽  
Serum Markers ◽  
Clinical Value ◽  
Serum Tumor Markers ◽  
Monitoring Therapy ◽  
Monitoring Treatment

Abstract Background: Although multiple serum-based tumor markers have been described for breast cancer, such as CA 15-3, BR 27.29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA. Methods: The literature relevant to serum tumor markers in breast cancer was reviewed. Particular attention was given to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. Results: Because of a lack of sensitivity for early disease and lack of specificity, none of the available markers is of value for the detection of early breast cancer. High preoperative concentrations of CA 15-3 are, however, associated with adverse patient outcome. Although serial determinations of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of ∼2–9 months, the clinical value of this lead time remains to be determined. Serum markers, however, are the only validated approach for monitoring treatment in patients with advanced disease that cannot be evaluated by use of conventional criteria. Conclusions: CA 15-3 is one of the first circulating prognostic factors for breast cancer. Preoperative concentrations thus might be combined with existing prognostic factors for predicting outcome in patients with newly diagnosed breast cancer. At present, the most important clinical application of CA 15-3 is in monitoring therapy in patients with advanced breast cancer that is not assessable by existing clinical or radiologic procedures.

scholarly journals Transcatheter Arterial Chemoembolization Is a Feasible Palliative Locoregional Therapy for Breast Cancer Liver Metastases

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Sung W. Cho ◽  
Krit Kitisin ◽  
David Buck ◽  
Jennifer Steel ◽  
Adam Brufsky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Transcatheter Arterial Chemoembolization ◽  
Hepatic Metastases ◽  
Median Number ◽  
Locoregional Therapy ◽  
Breast Cancer Patients ◽  
Kaplan Meier ◽  
Arterial Chemoembolization

Background. Liver metastases are common in advanced breast cancer. We sought to evaluate the role of transcatheter arterial chemoembolization (TACE) in breast cancer patients with hepatic metastases.Methods. A retrospective review of ten patients with breast cancer who were treated with TACE for unresectable liver metastases (1998–2008).Results. All patients, median age 46.5, had received prior systemic chemotherapies. Adriamycin was administered for 6, cisplatin/gemcitabine for 2, cisplatin for one and oxaliplatin for one patient. Median number of TACE cycles was 4. Kaplan Meier survival analysis showed an increase in median survival for patients who responded to treatment when compared to those who did not respond (24vs7 months,P=.02).Conclusions. This is one of the largest series of breast cancer patients with liver metastases treated with TACE. It suggests that TACE is a feasible palliative option and warrants further investigations.

Sign in / Sign up

Export Citation Format

Share Document